Back to Search
PAUL CHARLTON, M.D.
M.D.
Emergency Medicine Physician
NPI: 1699186692IndividualAccepts Medicare
Specialties, Licenses & Credentials
Student in an Organized Health Care Education/Training Program
Student in an Organized Health Care Education/Training Program
Code: 390200000X
Emergency Medicine PhysicianPrimary
Emergency Medicine
Code: 207P00000X
MD60757311(WA)
CMS Specialties
PrimaryEMERGENCY MEDICINE
Education
OTHER
Class of 2014
Research & Publications (20)
Effect of phenazine compounds XR11576 and XR5944 on DNA topoisomerases.
PMID 18679685·Cancer Chemother Pharmacol·2009
7-preclinical
Pan-caspase inhibitor VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitis.
PMID 19676126·Hepatology·2009
7-preclinical
All-sky LIGO search for periodic gravitational waves in the early fifth-science-run data.
PMID 19392186·Phys Rev Lett·2009
8-other
Search for gravitational-wave bursts from soft gamma repeaters.
PMID 19113401·Phys Rev Lett·2008
8-other
Mode of action of the novel phenazine anticancer agents XR11576 and XR5944.
PMID 17159600·Anticancer Drugs·2007
8-other
Structural basis for potent inhibition of the Aurora kinases and a T315I multi-drug resistant mutant form of Abl kinase by VX-680.
PMID 17240048·Cancer Lett·2007
8-other
Phenazine-1-carboxamides: structure-cytotoxicity relationships for 9-substituents and changes in the H-bonding pattern of the cationic side chain.
PMID 16216514·Bioorg Med Chem·2006
7-preclinical
Limits on gravitational-wave emission from selected pulsars using LIGO data.
PMID 15904354·Phys Rev Lett·2005
8-other
Upper limits on a stochastic background of gravitational waves.
PMID 16384203·Phys Rev Lett·2005
8-other
Preclinical anti-tumor activity of XR5944 in combination with carboplatin or doxorubicin in non-small-cell lung carcinoma.
PMID 16162971·Anticancer Drugs·2005
7-preclinical
Case report: the effect of physiotherapy and orthotic intervention, 40 years after stroke.
PMID 16245758·Physiother Res Int·2005
5-case
Antitumour activity of XR5944 in vitro and in vivo in combination with 5-fluorouracil and irinotecan in colon cancer cell lines.
PMID 15700035·Br J Cancer·2005
7-preclinical
Biological characterization of MLN944: a potent DNA binding agent.
PMID 14749475·Mol Cancer Ther·2004
7-preclinical
Design and synthesis of new templates derived from pyrrolopyrimidine as selective multidrug-resistance-associated protein inhibitors in multidrug resistance.
PMID 14998324·J Med Chem·2004
7-preclinical
XR5967, a novel modulator of plasminogen activator inhibitor-1 activity, suppresses tumor cell invasion and angiogenesis in vitro.
PMID 15090742·Anticancer Drugs·2004
8-other
Ex vivo characterization of XR11576 (MLN576) against ovarian cancer and other solid tumors.
PMID 15457125·Anticancer Drugs·2004
4-observational
Ex vivo reversal of chemoresistance by tariquidar (XR9576).
PMID 15457126·Anticancer Drugs·2004
4-observational
The ex vivo characterization of XR5944 (MLN944) against a panel of human clinical tumor samples.
PMID 15634657·Mol Cancer Ther·2004
4-observational
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
Via practice · 2 locations total
- Address
- 516 E NIZHONI BLVD
GALLUP, NM 87301 - Phone
- (505) 722-1165
Quick Facts
- NPI
- 1699186692
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 2
- Locations
- 2
- Years in Practice
- 12
- Publications
- 20
Are you this provider?
Claim Your Profile